Peripheral dopaminergic nerves

Nitric oxide synthase, choline acetyltransferase, catecholamine enzymes and neuropeptides and their colocalization in the anterior pelvic ganglion, the inferior mesenteric ganglion and the hypogastric nerve of the male guinea pig

By the indirect immunofluorescence method, the distribution of nitric oxide synthase (NOS)-like immunoreactivity (LI) and its possible colocalization with neuropeptide immunoreactivities, with two enzymes for the catecholamine synthesis pathway, tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH), as well as the enzyme for the acetylcholine synthesis pathway, choline acetyltransferase (ChAT) were studied in the anterior pelvic ganglion (APG), the inferior mesenteric ganglion (IMG) and the hypogastric nerve in the male guinea pig. The analyses were performed on tissues from intact animals, as well as after compression/ligation or cut of the hypogastric nerve. In some cases the colonic nerves were also cut. Analysis of the APG showed two main neuronal cell populations, one group containing NOS localized in the caudal part of the APG and one TH-positive group lacking NOS in its cranial part. The majority of the NOS-positive neurons contained ChAT-LI. Some NOS-positive cells did not contain detectable ChAT, but all ChAT-positive cells contained NOS. NOS neurons often contained peptides, including vasoactive intestinal peptide (VIP), neuropeptide tyrosine (NPY), somatostatin (SOM) and/or calcitonin gene-related peptide (CGRP). Some NOS cells expressed DBH, but never TH. The second cell group, characterized by absence of NOS, contained TH, mostly DBH and NPY and occasionally SOM and CGRP. Some TH-positive neurons lacked DBH. In the IMG, the NOS-LI was principally in nerve fibers, which were of two types, one consisting of strongly immunoreactive, coarse, varicose fibers with a patchy distribution, the other one forming fine, varicose, weakly immunoreactive fibers with a more general distribution. In the coarse networks, NOS-LI coexisted with VIP- and DYN-LI and the fibers surrounded mainly the SOM-containing noradrenergic principal ganglion cells. A network of ChAT-positive, often NOS-containing nerve fibers, surrounded the principal neurons. Occasional neuronal cell bodies in the IMG contained both NOS- and ChAT-LI. Accumulation of NOS was observed, both caudal and cranial, to a crush of the hypogastric nerve. VIP accumulated mainly on the caudal side and often coexisted with NOS. NPY accumulated on both sides of the crush, but mainly on the cranial side, and ENK was exclusively on the cranial side. Neither peptide coexisted with NOS. Both substance P (SP) and CGRP showed the strongest accumulation on the cranial side, possibly partly colocalized with NOS. It is concluded that the APG in the male guinea-pig consists of two major complementary neuron populations, the cholinergic neurons always containing NOS and the noradrenergic neurons containing TH and DBH. Some NOS neurons lacked ChAT and could represent truly non-adrenergic, non-cholinergic neurons. In addition, there may be a small dopaminergic neuron population, that is containing TH but lacking DBH. The cholinergic NOS neurons contain varying combinations of peptides. The noradrenergic population often contained NPY and occasionally SOM and CGRP. It is suggested that NO may interact with a number of other messenger molecules to play a role both within the APG and IMG and also in the projection areas of the APG.

Distribution and origin of aminergic neurones in dog small intestine

In dog ileum, axons containing immunoreactivity for tyrosine hydroxylase (TH) and for DOPA decarboxylase (DDC) invest the neurones of the enteric ganglia and are present around arterioles, in the deep plexus of the circular muscle and in the laminar propria of the mucosal villi. Immunoreactivity for serotonin (5-HT) was present in mucosal enterochromaffin cells and in varicose axons investing cells of the submucous plexus, but not in axons in myenteric plexus, circular muscle or mucosa. No enteric neuronal cell bodies were immunoreactive for DDC or for 5-HT. Two weeks after extrinsic denervation of the ileum, all TH staining was absent. By contrast, the pattern of DDC staining was unchanged, except around blood vessels. We conclude that motility of dog ileum is likely to be regulated by sympathetic noradrenergic inputs and by intrinsic serotonergic and 'amine-handling' neurones. Dopaminergic innervation of dog ileum appears to be restricted to a sparse vasomotor supply.

Involvement of dopamine in control of renal blood flow

Previous studies have shown that the renal nerve supply in the dog contains a population of dopaminergic vasodilator neurons. In order to obtain more information on the possible physiological functions of these neurons, we examined two situations in which there is existing evidence for active intrarenal vasodilation--the reflex response to coronary artery occlusion and the autoregulatory response to reduced renal perfusion pressure. We were unable to confirm published reports that coronary artery occlusion evokes renal vasodilation. However, our results support the view that dopaminergic nerves participate in maintenance of renal blood flow and glomerular filtration at perfusion pressures around the lower limit of autoregulation.

A pharmacological comparison of [3H]GBR12935 binding to rodent striatal and kidney homogenates: binding to dopamine transporters?

Binding of [3H]GBR12935 to homogenates of mouse and rat striatum and kidney was studied. [3H]GBR12935 bound to both tissue preparations with high affinity (mouse striatum Kd = 2.4 +/- 0.4 nM, n = 4; mouse kidney Kd = 3.8 +/- 0.9 nM, n = 4), in a saturable (striatal Bmax = 1.5 +/- 0.4 pmol/mg protein; kidney Bmax = 4.9 +/- 0.5 pmol/mg protein) and reversible manner. Saturation experiments revealed the presence of a single class of high affinity binding sites in both tissues of both species. Mouse kidney appeared to possess a greater density of [3H]GBR12935 binding sites than the striatum while the reverse situation prevailed for the rat. Although two dopamine uptake inhibitors, namely GBR12909 and benztropine, displaced [3H]GBR12935 binding from striatal and kidney homogenates with a similar affinity in both tissues of these species, unlabelled mazindol, (+/-)cocaine, nomifensine and amfonelic acid were significantly (P < 0.001-0.02) more potent inhibitors of [3H]GBR12935 binding in the striatum than in the kidney. While the pharmacological profile of [3H]GBR12935 binding in the rodent striatum compared well with that of the dopamine transporter reported previously, the pharmacology in the kidney was considerably different to that in the striatum. GBR12909 (1-30 mg/kg, i.p.), a close analog of GBR12935, induced significant antidiuretic and antinatriuretic effects in spontaneously hypertensive rats. These data suggest that while [3H]GBR12935 labels the dopamine uptake sites in the brain, it does not appear to label similar sites in the kidney. The mechanism of action of GBR12909 on sodium and water excretion remains to be determined.

Sympathetic innervation of the liver in man and dog: an immunohistochemical study

The sympathetic innervation of human and dog livers was examined by immunohistochemical localization of neuron-specific enolase to visualize the total complement of hepatic nerves and the localization of two enzymes involved in catecholamine synthesis, tyrosine hydroxylase and dihydroxyphenylalanine decarboxylase, to visualize sympathetic nerves. Similar results were obtained for both man and dog. About 60% of the non-myelinated axons supplying the hepatic parenchyma, and virtually all those supplying the vasculature, appeared to be sympathetic. The pattern of dihydroxyphenylalanine decarboxylase immunoreactivity was compatible with innervation of the intrahepatic hepatic arteries and portal veins by dopaminergic as well as by noradrenergic sympathetic nerves. By contrast, there was no evidence for a dopaminergic component in the parenchymal sympathetic innervation.

Involvement of endogenous dopamine and DA-1 receptors in the renal effects of atrial natriuretic factor in rats

The precise mechanism of the diuretic and natriuretic effects of Atrial Natriuretic Factor (ANF) is still unclear. The present study was undertaken with the aim of elucidating the mechanism of interaction between ANF, dopamine (DA) and DA receptors in the renal effects of ANF in rats. In pentobarbital anesthetized rats, ANF infusion (10 micrograms/kg/hour) produced marked diuresis and natriuresis which was accompanied by significant hypotension, bradycardia and also a modest increase in glomerular filtration rate. However, there was no accompanying increase in urinary DA excretion during ANF infusion. Pretreatment with SCH 23390, a selective DA-1 receptor antagonist caused significant attenuation of the diuretic and natriuretic effects of ANF whereas the hemodynamic changes produced by ANF were still evident in SCH 23390 treated animals. Plasma ANF levels were elevated to the same magnitude in both the control and SCH 23390 treated groups. Pretreatment with carbidopa, a dopa decarboxylase inhibitor also significantly blunted the diuretic and natriuretic effects of ANF. The antagonism of the ANF-induced diuresis and natriuresis by SCH 23390 and carbidopa was comparable in magnitude. These results suggest that endogenous DA, via activation of DA-1 receptors plays a permissive role in the renal effects of ANF, perhaps by enhancing tubular responsiveness to ANF. However, there does not appear to be a stimulatory effect of ANF on renal DA production or release.

A functional role for renal dopaminergic nerves in the dog

1. Efferent renal nerve stimulation at 5 Hz causes secretion of both dopamine (DA) and noradrenaline (NA) into renal venous plasma. DA comprises about 8% of the total catecholamine overflow; by contrast, DA efflux into femoral venous plasma following stimulation of the lumbar sympathetic nerves is 1% or less of total catecholamine. 2. Intact, but not denervated, kidneys of volume-loaded dogs also secrete both dopamine (DA) and noradrenaline (NA) into renal venous blood at rest, but the DA:NA ratio is considerably higher than that evoked by nerve stimulation. 3. Acute animal treatment with 6-hydroxydopamine (6-OHDA) abolishes stimulus-evoked catecholamine overflow and the usual fall in glomerular filtration and sodium and water excretion that accompanies renal nerve activation. 4. When 6-OHDA is administered in the presence of a selective inhibitor of UptakeDA (GBR 12909), stimulus-evoked DA overflow is selectively protected against the effect of 6-OHDA. Under these circumstances, nerve stimulation increases glomerular filtration and excretion of water, but not of sodium. These effects are abolished by DA1 receptor blockade. 5. These data indicate that DA is released from intrarenal dopaminergic nerve terminals in vivo, both in response to direct nerve stimulation and tonically under conditions of volume expansion. The main effects of dopaminergic nerve activation are juxtaglomerular vasodilatation and inhibition of distal tubular water reabsorption.